Influence of angiotensin receptor and converting enzyme blockers therapy in the respiratory outcome of COVID-19 hospitalized patients
Copyright © 2023 Elsevier España, S.L.U. All rights reserved..
OBJECTIVES: COVID-19, caused by SARS-CoV-2, has spread around the world since 2019. In severe cases, COVID-19 can lead to hospitalization and death. Systemic arterial hypertension and other comorbidities are associated with serious COVID-19 infection. Literature is unclear whether antihypertensive therapy with angiotensin receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors affect COVID-19 outcomes. We aim to assess whether ACEI/ARB therapy is a risk factor for worse respiratory outcomes related to COVID-19 in hospitalized patients.
METHODS: Retrospective study enrolling admitted COVID-19-diagnosed patients by RT-PCR at the Hospital Geral de Fortaleza, Brazil, during 2021. Patient medical records, sociodemographic, and clinical data were analyzed. Chest CT images were analyzed using CAD4COVID-CT/Thirona™ software.
RESULTS: A total of 294 patients took part in the study. A cut-off point of 66% of pulmonary involvement was found by ROC curve, with patients having higher risk of death and intubation and lower 60-day survival. Advanced age (RR 1.025, P=0.001) and intubation (RR 16.747, P<0.001) were significantly associated with a higher risk of death. Advanced age (RR 1.023, P=0.001) and the use of noninvasive ventilation (RR 1.548, P=0.037) were associated with a higher risk of intubation. Lung involvement (>66%) increased the risk of death by almost 2.5-fold (RR 2.439, P<0.001) and by more than 2.3-fold the risk of intubation (RR 2.317, P<0.001).
CONCLUSIONS: Altogether, our findings suggest that ACEI or ARB therapy does not affect the risk of death and disease course during hospitalization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:162 |
|---|---|
| Enthalten in: |
Medicina clinica - 162(2024), 4 vom: 23. Feb., Seite 163-169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lima, Felipe B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.02.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medcli.2023.10.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364921919 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364921919 | ||
| 003 | DE-627 | ||
| 005 | 20240327235450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medcli.2023.10.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1350.xml |
| 035 | |a (DE-627)NLM364921919 | ||
| 035 | |a (NLM)38000940 | ||
| 035 | |a (PII)S0025-7753(23)00605-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lima, Felipe B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influence of angiotensin receptor and converting enzyme blockers therapy in the respiratory outcome of COVID-19 hospitalized patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a OBJECTIVES: COVID-19, caused by SARS-CoV-2, has spread around the world since 2019. In severe cases, COVID-19 can lead to hospitalization and death. Systemic arterial hypertension and other comorbidities are associated with serious COVID-19 infection. Literature is unclear whether antihypertensive therapy with angiotensin receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors affect COVID-19 outcomes. We aim to assess whether ACEI/ARB therapy is a risk factor for worse respiratory outcomes related to COVID-19 in hospitalized patients | ||
| 520 | |a METHODS: Retrospective study enrolling admitted COVID-19-diagnosed patients by RT-PCR at the Hospital Geral de Fortaleza, Brazil, during 2021. Patient medical records, sociodemographic, and clinical data were analyzed. Chest CT images were analyzed using CAD4COVID-CT/Thirona™ software | ||
| 520 | |a RESULTS: A total of 294 patients took part in the study. A cut-off point of 66% of pulmonary involvement was found by ROC curve, with patients having higher risk of death and intubation and lower 60-day survival. Advanced age (RR 1.025, P=0.001) and intubation (RR 16.747, P<0.001) were significantly associated with a higher risk of death. Advanced age (RR 1.023, P=0.001) and the use of noninvasive ventilation (RR 1.548, P=0.037) were associated with a higher risk of intubation. Lung involvement (>66%) increased the risk of death by almost 2.5-fold (RR 2.439, P<0.001) and by more than 2.3-fold the risk of intubation (RR 2.317, P<0.001) | ||
| 520 | |a CONCLUSIONS: Altogether, our findings suggest that ACEI or ARB therapy does not affect the risk of death and disease course during hospitalization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Angiotensin-converting enzyme 2 | |
| 650 | 4 | |a Antihipertensivos | |
| 650 | 4 | |a Antihypertensive agents | |
| 650 | 4 | |a Artificial intelligence | |
| 650 | 4 | |a Enzima convertidora de angiotensina 2 | |
| 650 | 4 | |a Hipertensión | |
| 650 | 4 | |a Hypertension | |
| 650 | 4 | |a Inteligencia artificial | |
| 650 | 4 | |a Lung | |
| 650 | 4 | |a Pulmón | |
| 650 | 4 | |a Renin–angiotensin system | |
| 650 | 4 | |a Sistema renina-angiotensina | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Receptors, Angiotensin |2 NLM | |
| 700 | 1 | |a Muniz, Francisco Wilker Mustafa Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Meneses, Gdayllon C |e verfasserin |4 aut | |
| 700 | 1 | |a Bezerra, Karine C |e verfasserin |4 aut | |
| 700 | 1 | |a Moreira, Carolyne N |e verfasserin |4 aut | |
| 700 | 1 | |a Aguiar, André P |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento, José Carlos R |e verfasserin |4 aut | |
| 700 | 1 | |a Veras de S Freitas, Tainá |e verfasserin |4 aut | |
| 700 | 1 | |a de Bruin, Pedro Felipe C |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Eanes Delgado B |e verfasserin |4 aut | |
| 700 | 1 | |a Daher, Elizabeth de F |e verfasserin |4 aut | |
| 700 | 1 | |a Oriá, Reinaldo B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica |d 1948 |g 162(2024), 4 vom: 23. Feb., Seite 163-169 |w (DE-627)NLM000359017 |x 1578-8989 |7 nnns |
| 773 | 1 | 8 | |g volume:162 |g year:2024 |g number:4 |g day:23 |g month:02 |g pages:163-169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medcli.2023.10.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 162 |j 2024 |e 4 |b 23 |c 02 |h 163-169 | ||